Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 1Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Urogenital Neoplasms 1Sarcoma 1Neoplasms 1Melanoma 1Lung Neoplasms 1Hypertension 1Head and Neck Neoplasms 1Diabetes Mellitus 1Depressive Disorder, Major 1Depression 1Colorectal Neoplasms 1Cardiovascular Diseases 1Breast Neoplasms 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 4gamma-Globulins 3Standard of Care 3Oxaliplatin 3Melatonin 3Gemcitabine 3Fluorouracil 3Drug Therapy 3Ciprofloxacin 3Capecitabine 3pertuzumab 2entrectinib 2cobimetinib 2capmatinib 2atezolizumab 2alectinib 2Water 2Vemurafenib 2Trastuzumab 2Sirolimus 2Saline Solution 2Pemetrexed 2Methylphenidate 2Lidocaine 2Leucovorin 2Immunoglobulins, Intravenous 2Docetaxel 2Dexmedetomidine 2Cisplatin 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Neoplasms × Fatty Acids, Omega-3 × Clear all
NCT01803711 2017-12-27

Omega 3 FA Supplements as Augmentation in the Treatment of Depression

UConn Health

Phase 2/3 Terminated
6 enrolled 4 charts

Cardiovascular Diseases, Depression, Depressive Disorder, Major, Diabetes Mellitus, Hypertension, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡